US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Palvella Therapeutics

151.24

-1.3500-0.88%

Volume:10.82K

Turnover:1.63M

Market Cap:2.18B

PE:-30.88

High:151.24

Open:150.00

Low:150.00

Close:152.59

52wk High:161.38

52wk Low:50.82

Shares:14.41M

Float Shares:8.40M

Volume Ratio:0.43

T/O Rate:0.13%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-4.8978

EPS(LYR):-3.7076

ROE:-46.63%

ROA:-22.05%

PB:10.05

PE(LYR):-40.79

Loading ...

Overview Company News Filings

Palvella director George M. Jenkins acquires PVLA shares worth 0.1 million

Stock Track | Palvella Therapeutics Soars 5.58% Intraday on Analyst Price Target Hikes

Palvella Therapeutics Inc : Raymond James Raises Target Price to $225 From $193

THOMSON REUTERS

Chardan Raises Price Target on Palvella Therapeutics to $240 From $210, Keeps Buy Rating

MT Newswires Live

Positive Risk‑Reward on PVLA Driven by Low‑Risk QTORIN Rapamycin NDA and Strong Cash Runway

Palvella Therapeutics Is Maintained at Buy by Chardan Capital

Palvella Therapeutics price target raised to $210 from $200 at Oppenheimer

Stock Track | Palvella Therapeutics Soars 6.18% Intraday on Narrowed Loss and Positive Clinical Updates

Palvella Therapeutics 2025 Net Loss Narrows

MT Newswires Live

BRIEF-Palvella Therapeutics Reports Full Year 2025 Financial Results And Provides Corporate Update

Earnings Flash (PVLA) Palvella Posts 2025 Loss $3.71 a Share, vs. FactSet Est of $3.57 Loss

MT Newswires Live

Palvella Therapeutics Q4 EPS $(1.08) Misses $(0.91) Estimate

Benzinga Earnings

Palvella Therapeutics Inc - Phase 3 Trial of Qtorin Rapamycin for Cutaneous Vms Planned for 2H 2026

THOMSON REUTERS

Palvella Therapeutics - Nda for Qtorin Rapamycin for Treatment of Microcystic Lymphatic Malformations on Track for Planned Submission in H2 2026

THOMSON REUTERS

Palvella Therapeutics Inc - Phase 2 Trial of Qtorin Rapamycin for Angiokeratomas Planned for Q2 2026

THOMSON REUTERS

Press Release: Palvella Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update

Palvella says QTORIN rapamycin gel meets primary endpoint in Phase 3 SELVA trial

Palvella Therapeutics Announces Scientific Publication in Journal of Vascular Anomalies Highlighting the Infiltrative Growth and Therapeutic Challenges of Microcystic Lymphatic Malformations

Calendar of U.S. Earnings Expected in the Week Ahead

Palvella Therapeutics announces Phase 2 DSAP trial start in H2 2026; Phase 3 SELVA study meets primary endpoint on mLM-IGA (p<0.001)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/PVLA/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PVLA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PVLA\",,,,,undefined,":{"symbol":"PVLA","market":"US","secType":"STK","nameCN":"Palvella Therapeutics","latestPrice":151.24,"timestamp":1788272154743,"preClose":152.59,"halted":0,"volume":10817,"delay":0,"changeRate":-0.008847237695786056,"floatShares":8398100,"shares":14408407,"eps":-4.897784,"marketStatus":"Trading","change":-1.35,"latestTime":"09-01 10:15:55 EDT","open":150,"high":151.24,"low":150,"amount":1629766.1288700001,"amplitude":0.008126,"askPrice":151.9,"askSize":3,"bidPrice":150.59,"bidSize":33,"shortable":3,"etf":0,"ttmEps":-4.897784,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1788292800000},"marketStatusCode":2,"adr":0,"listingDate":1435636800000,"exchange":"NASDAQ","adjPreClose":152.59,"preHourTrading":{"tag":"盘前","latestPrice":150.42,"preClose":152.59,"latestTime":"09:29 EDT","volume":1174,"amount":179085.10632,"timestamp":1788269376068,"change":-2.17,"changeRate":-0.014221,"amplitude":0.02143},"postHourTrading":{"tag":"盘后","latestPrice":152.59,"preClose":152.59,"latestTime":"19:30 EDT","volume":10924,"amount":1667043.55196,"timestamp":1788219002401,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.433837,"impliedVol":0.5099,"impliedVolPercentile":0.0556},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PVLA\",,,,,undefined,":{"symbol":"PVLA","floatShares":8398100,"roa":"-22.05%","roe":"-46.63%","lyrEps":-3.707588,"volumeRatio":0.433837,"shares":14408407,"dividePrice":0,"high":151.24,"amplitude":0.008126,"preClose":152.59,"low":150,"week52Low":50.82,"pbRate":"10.05","week52High":161.38,"institutionHeld":0,"latestPrice":151.24,"committee":0.833333,"eps":-4.897784,"divideRate":0,"volume":10817,"delay":0,"ttmEps":-4.897784,"open":150,"prevYearClose":104.67,"prevWeekClose":149.97,"prevMonthClose":152.59,"prevQuarterClose":152.82,"fiveDayClose":148.24,"twentyDayClose":151.99,"sixtyDayClose":108.67},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PVLA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-04","symbol":"PVLA","fiscalQuarterEnding":"2026/06","expectedEps":-1.16,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1785816000000,"reportTimeType":"pre","actualEps":-1.52},{"market":"US","date":"2026-05-07","symbol":"PVLA","fiscalQuarterEnding":"2026/03","expectedEps":-0.9,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778126400000,"reportTimeType":"pre","actualEps":-1.2},{"market":"US","date":"2026-03-31","symbol":"PVLA","fiscalQuarterEnding":"2025/12","expectedEps":-0.95,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1774929600000,"reportTimeType":"pre","actualEps":-1.08},{"market":"US","date":"2025-11-11","symbol":"PVLA","fiscalQuarterEnding":"2025/09","expectedEps":-0.85,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1762837200000,"reportTimeType":"pre","actualEps":-1.03},{"market":"US","date":"2025-08-14","symbol":"PVLA","fiscalQuarterEnding":"2025/06","expectedEps":-0.78,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"pre","actualEps":-0.86}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PVLA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PVLA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.75,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.75,"analysts":16,"updateTime":1778731200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PVLA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PVLA","date":"2026-08-31","current":-30.830269,"percent":0.275294,"low":-60.48704,"twenty":-36.922579,"median":-28.436723,"eighty":-10.987175,"high":46.119317,"avg":-19.78197,"sd":24.362339,"marketCap":2160828797},"quantilePoints":[{"date":"2024-12-20","current":19.163371,"twenty":19.017062,"median":19.163371,"eighty":20.457893,"marketCap":135216749},{"date":"2024-12-27","current":19.083855,"twenty":18.842127,"median":19.083855,"eighty":19.659551,"marketCap":134655684},{"date":"2025-01-03","current":21.071757,"twenty":18.969352,"median":19.083855,"eighty":19.907642,"marketCap":148682317},{"date":"2025-01-10","current":22.216788,"twenty":19.083855,"median":19.083855,"eighty":21.987782,"marketCap":156761658},{"date":"2025-01-17","current":20.960435,"twenty":19.083855,"median":20.523096,"eighty":21.13537,"marketCap":147896826},{"date":"2025-01-24","current":19.863113,"twenty":19.083855,"median":20.650322,"eighty":21.071757,"marketCap":140154124},{"date":"2025-01-31","current":20.674177,"twenty":19.083855,"median":20.658273,"eighty":21.151273,"marketCap":145876991},{"date":"2025-02-07","current":24.729496,"twenty":19.083855,"median":20.674177,"eighty":22.089563,"marketCap":174491323},{"date":"2025-02-14","current":31.090781,"twenty":19.083855,"median":20.912725,"eighty":23.46519,"marketCap":219376551},{"date":"2025-02-21","current":30.565975,"twenty":19.147468,"median":20.992241,"eighty":24.783567,"marketCap":215673520},{"date":"2025-02-28","current":30.804523,"twenty":19.723165,"median":21.111515,"eighty":29.913943,"marketCap":217356716},{"date":"2025-03-07","current":39.042387,"twenty":20.066674,"median":21.469337,"eighty":30.728188,"marketCap":275483086},{"date":"2025-03-14","current":43.678174,"twenty":20.34657,"median":22.439433,"eighty":31.793703,"marketCap":308193196},{"date":"2025-03-21","current":44.751641,"twenty":20.49288,"median":23.46519,"eighty":33.810231,"marketCap":315767578},{"date":"2025-03-28","current":44.688028,"twenty":20.604203,"median":24.292158,"eighty":40.654974,"marketCap":315318726},{"date":"2025-04-04","current":-15.155991,"twenty":19.723165,"median":23.46519,"eighty":39.236406,"marketCap":264229553},{"date":"2025-04-11","current":-13.752893,"twenty":19.083855,"median":22.439433,"eighty":38.266311,"marketCap":239767934},{"date":"2025-04-17","current":-15.396161,"twenty":19.00752,"median":21.77945,"eighty":36.545583,"marketCap":268416676},{"date":"2025-04-25","current":-16.047148,"twenty":-12.608925,"median":21.151273,"eighty":34.239617,"marketCap":279765986},{"date":"2025-05-02","current":-15.493342,"twenty":-14.192783,"median":21.008144,"eighty":33.36176,"marketCap":270110923},{"date":"2025-05-09","current":-14.42287,"twenty":-14.682214,"median":20.912725,"eighty":33.091405,"marketCap":251448313},{"date":"2025-05-16","current":-10.548775,"twenty":-14.614161,"median":20.674177,"eighty":32.251716,"marketCap":243497378},{"date":"2025-05-23","current":-10.577479,"twenty":-14.552086,"median":20.64237,"eighty":31.796884,"marketCap":244159956},{"date":"2025-05-30","current":-11.868448,"twenty":-14.483678,"median":20.515145,"eighty":31.510626,"marketCap":273959378},{"date":"2025-06-06","current":-11.250599,"twenty":-14.245514,"median":19.990339,"eighty":31.090781,"marketCap":259697570},{"date":"2025-06-13","current":-12.65393,"twenty":-13.898957,"median":19.083855,"eighty":30.976278,"marketCap":292090669},{"date":"2025-06-20","current":-9.82332,"twenty":-13.773118,"median":19.083855,"eighty":30.785439,"marketCap":226751689},{"date":"2025-06-27","current":-9.876005,"twenty":-13.751337,"median":19.083855,"eighty":30.680478,"marketCap":227967812},{"date":"2025-07-03","current":-11.552339,"twenty":-13.745115,"median":18.829404,"eighty":30.565975,"marketCap":266662639},{"date":"2025-07-11","current":-12.902986,"twenty":-13.143371,"median":-9.82332,"eighty":30.216104,"marketCap":297839615},{"date":"2025-07-18","current":-14.957693,"twenty":-13.611836,"median":-10.196903,"eighty":29.977556,"marketCap":345268417},{"date":"2025-07-25","current":-18.501942,"twenty":-13.979479,"median":-10.548775,"eighty":29.89804,"marketCap":427080338},{"date":"2025-08-01","current":-17.520089,"twenty":-14.593892,"median":-10.570486,"eighty":26.844623,"marketCap":404416225},{"date":"2025-08-08","current":-18.703103,"twenty":-14.909501,"median":-10.577479,"eighty":25.683689,"marketCap":431723718},{"date":"2025-08-15","current":-17.957373,"twenty":-15.155991,"median":-10.795594,"eighty":24.999851,"marketCap":509666156},{"date":"2025-08-22","current":-19.99406,"twenty":-15.421442,"median":-10.987175,"eighty":24.729496,"marketCap":567471411},{"date":"2025-08-29","current":-19.990163,"twenty":-15.528887,"median":-11.165181,"eighty":23.854819,"marketCap":567360814},{"date":"2025-09-05","current":-21.096831,"twenty":-16.235493,"median":-11.305678,"eighty":23.549477,"marketCap":598770263},{"date":"2025-09-12","current":-22.776317,"twenty":-17.271569,"median":-11.413443,"eighty":23.46678,"marketCap":646437419},{"date":"2025-09-19","current":-23.006223,"twenty":-17.715742,"median":-11.554734,"eighty":23.433384,"marketCap":652962621},{"date":"2025-09-26","current":-22.480166,"twenty":-18.057474,"median":-11.868448,"eighty":22.814749,"marketCap":638032073},{"date":"2025-10-03","current":-24.405145,"twenty":-18.52589,"median":-11.961844,"eighty":22.305846,"marketCap":692666818},{"date":"2025-10-10","current":-27.312096,"twenty":-18.938434,"median":-12.127082,"eighty":22.115008,"marketCap":775171919},{"date":"2025-10-17","current":-28.500595,"twenty":-19.602341,"median":-12.457671,"eighty":21.593382,"marketCap":808903898},{"date":"2025-10-24","current":-27.783599,"twenty":-20.103168,"median":-12.65393,"eighty":21.227608,"marketCap":788554114},{"date":"2025-10-31","current":-30.558062,"twenty":-20.870432,"median":-12.719639,"eighty":21.154454,"marketCap":867298929},{"date":"2025-11-07","current":-30.639894,"twenty":-21.250362,"median":-12.96286,"eighty":21.08766,"marketCap":869621458},{"date":"2025-11-14","current":-28.915921,"twenty":-22.006325,"median":-13.231068,"eighty":21.033589,"marketCap":952837445},{"date":"2025-11-21","current":-32.881534,"twenty":-22.215189,"median":-13.745115,"eighty":20.998602,"marketCap":1083512294},{"date":"2025-11-28","current":-36.922579,"twenty":-22.816843,"median":-13.778174,"eighty":20.973157,"marketCap":1216672807},{"date":"2025-12-05","current":-33.693335,"twenty":-23.242364,"median":-14.278382,"eighty":20.931809,"marketCap":1110262762},{"date":"2025-12-12","current":-34.763763,"twenty":-24.512694,"median":-14.593892,"eighty":20.769596,"marketCap":1145535502},{"date":"2025-12-19","current":-34.569792,"twenty":-27.267674,"median":-14.831115,"eighty":20.674177,"marketCap":1139143797},{"date":"2025-12-26","current":-38.014559,"twenty":-27.693195,"median":-14.933597,"eighty":20.674177,"marketCap":1252655736},{"date":"2026-01-02","current":-37.597882,"twenty":-28.489684,"median":-15.118842,"eighty":20.670996,"marketCap":1238925408},{"date":"2026-01-09","current":-34.979285,"twenty":-28.647112,"median":-15.258978,"eighty":20.655092,"marketCap":1152637396},{"date":"2026-01-16","current":-37.350031,"twenty":-29.232399,"median":-15.408801,"eighty":20.639189,"marketCap":1230758230},{"date":"2026-01-23","current":-33.075504,"twenty":-29.325414,"median":-15.443563,"eighty":20.626467,"marketCap":1089903999},{"date":"2026-01-30","current":-29.418807,"twenty":-29.517639,"median":-15.528887,"eighty":20.515145,"marketCap":969408531},{"date":"2026-02-06","current":-27.453961,"twenty":-29.48062,"median":-16.091391,"eighty":20.403822,"marketCap":904662930},{"date":"2026-02-13","current":-29.461912,"twenty":-29.48062,"median":-17.007828,"eighty":20.117564,"marketCap":970828909},{"date":"2026-02-20","current":-29.573265,"twenty":-29.488024,"median":-17.242297,"eighty":19.914003,"marketCap":974498221},{"date":"2026-02-27","current":-60.48704,"twenty":-29.707799,"median":-17.512905,"eighty":19.303319,"marketCap":1993168926},{"date":"2026-03-06","current":-55.02714,"twenty":-30.090518,"median":-17.81704,"eighty":19.099758,"marketCap":1813254325},{"date":"2026-03-13","current":-55.699943,"twenty":-30.574428,"median":-17.963839,"eighty":19.083855,"marketCap":1835424534},{"date":"2026-03-20","current":-46.447881,"twenty":-31.137829,"median":-18.431476,"eighty":19.083855,"marketCap":1530550575},{"date":"2026-03-27","current":-47.956591,"twenty":-32.06614,"median":-18.561811,"eighty":19.083855,"marketCap":1580265588},{"date":"2026-04-02","current":-41.305964,"twenty":-32.945472,"median":-18.707892,"eighty":19.083855,"marketCap":1723078270},{"date":"2026-04-10","current":-44.675498,"twenty":-33.393759,"median":-19.095844,"eighty":19.083855,"marketCap":1863638401},{"date":"2026-04-17","current":-42.609857,"twenty":-34.004406,"median":-19.561706,"eighty":18.969352,"marketCap":1777470174},{"date":"2026-04-24","current":-43.594639,"twenty":-34.788907,"median":-19.977117,"eighty":18.816681,"marketCap":1818550375},{"date":"2026-05-01","current":-44.030414,"twenty":-35.208457,"median":-20.266831,"eighty":18.756249,"marketCap":1836728722},{"date":"2026-05-08","current":-32.885673,"twenty":-35.663927,"median":-20.816267,"eighty":1.605963,"marketCap":1621165018},{"date":"2026-05-15","current":-34.614036,"twenty":-35.663927,"median":-21.021819,"eighty":-9.854931,"marketCap":1706368150},{"date":"2026-05-22","current":-33.726646,"twenty":-35.536117,"median":-21.24101,"eighty":-10.054175,"marketCap":1662622476},{"date":"2026-05-29","current":-33.709189,"twenty":-35.477208,"median":-21.439742,"eighty":-10.192113,"marketCap":1661761905},{"date":"2026-06-05","current":-33.406604,"twenty":-35.361812,"median":-22.020353,"eighty":-10.267821,"marketCap":1646845348},{"date":"2026-06-12","current":-30.951006,"twenty":-35.258528,"median":-22.098288,"eighty":-10.422477,"marketCap":1525791744},{"date":"2026-06-18","current":-32.769429,"twenty":-35.21133,"median":-22.480166,"eighty":-10.551201,"marketCap":1615434519},{"date":"2026-06-26","current":-39.627064,"twenty":-35.273781,"median":-22.826974,"eighty":-10.561865,"marketCap":1953495352},{"date":"2026-07-02","current":-40.226416,"twenty":-35.557603,"median":-22.973101,"eighty":-10.565696,"marketCap":1983041611},{"date":"2026-07-10","current":-43.944726,"twenty":-36.020976,"median":-23.275097,"eighty":-10.575275,"marketCap":2166343157},{"date":"2026-07-17","current":-42.993327,"twenty":-36.290379,"median":-24.416835,"eighty":-10.577479,"marketCap":2119442057},{"date":"2026-07-24","current":-41.665152,"twenty":-36.922579,"median":-25.632611,"eighty":-10.577479,"marketCap":2053966975},{"date":"2026-07-31","current":-43.697421,"twenty":-37.223591,"median":-27.238059,"eighty":-10.749704,"marketCap":2154151740},{"date":"2026-08-07","current":-36.182159,"twenty":-37.223591,"median":-27.449273,"eighty":-10.795027,"marketCap":2232294496},{"date":"2026-08-14","current":-36.560492,"twenty":-37.14313,"median":-27.55759,"eighty":-10.795594,"marketCap":2255636115},{"date":"2026-08-21","current":-33.297956,"twenty":-36.964247,"median":-27.969419,"eighty":-10.845405,"marketCap":2054350670},{"date":"2026-08-28","current":-35.107881,"twenty":-36.922579,"median":-28.427404,"eighty":-10.961312,"marketCap":2166015824},{"date":"2026-08-31","current":-35.023807,"twenty":-36.922579,"median":-28.436723,"eighty":-10.987175,"marketCap":2160828797}],"updateTime":1788272155386},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PVLA\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2624919549","title":"Palvella director George M. Jenkins acquires PVLA shares worth 0.1 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2624919549","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624919549?lang=en_us&edition=fundamental","pubTime":"2026-04-02 04:06","pubTimestamp":1775074010,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics director George M. Jenkins reported an open-market purchase of 445 common shares at USD 112.3 per share.Directly held stake rose to 187,616 common shares following transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Palvella Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 01, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL8RZCMS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Palvella director George M. Jenkins acquires PVLA shares worth 0.1 million","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187347316","title":"Stock Track | Palvella Therapeutics Soars 5.58% Intraday on Analyst Price Target Hikes","url":"https://stock-news.laohu8.com/highlight/detail?id=1187347316","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187347316?lang=en_us&edition=fundamental","pubTime":"2026-04-01 21:35","pubTimestamp":1775050548,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics (PVLA) saw its stock price soar 5.58% during intraday trading on Wednesday, driven by positive analyst sentiment.The surge follows pre-market announcements from two research...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624590664","title":"Palvella Therapeutics Inc : Raymond James Raises Target Price to $225 From $193","url":"https://stock-news.laohu8.com/highlight/detail?id=2624590664","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624590664?lang=en_us&edition=fundamental","pubTime":"2026-04-01 19:19","pubTimestamp":1775042380,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nFWN40K0QV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PVLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624590589","title":"Chardan Raises Price Target on Palvella Therapeutics to $240 From $210, Keeps Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2624590589","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624590589?lang=en_us&edition=fundamental","pubTime":"2026-04-01 19:15","pubTimestamp":1775042122,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics (PVLA) has an average rating of buy and mean price target of $229.44, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from ma","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624552089","title":"Positive Risk‑Reward on PVLA Driven by Low‑Risk QTORIN Rapamycin NDA and Strong Cash Runway","url":"https://stock-news.laohu8.com/highlight/detail?id=2624552089","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624552089?lang=en_us&edition=fundamental","pubTime":"2026-04-01 08:35","pubTimestamp":1775003743,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Ritu Baral maintained a Buy rating on Palvella Therapeutics yesterday and set a price target of $267.00. Ritu Baral has given his ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/positive-risk‑reward-on-pvla-driven-by-low‑risk-qtorin-rapamycin-nda-and-strong-cash-runway-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/positive-risk‑reward-on-pvla-driven-by-low‑risk-qtorin-rapamycin-nda-and-strong-cash-runway-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624104553","title":"Palvella Therapeutics Is Maintained at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2624104553","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624104553?lang=en_us&edition=fundamental","pubTime":"2026-04-01 05:19","pubTimestamp":1774991940,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PVLA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 31, 2026 17:19 ET (21:19 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624534789","title":"Palvella Therapeutics price target raised to $210 from $200 at Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2624534789","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624534789?lang=en_us&edition=fundamental","pubTime":"2026-04-01 02:51","pubTimestamp":1774983082,"startTime":"0","endTime":"0","summary":"Oppenheimer raised the firm’s price target on Palvella Therapeutics (PVLA) to $210 from $200 and keeps an Outperform rating on the shares. The firm...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-price-target-raised-to-210-from-200-at-oppenheimer-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-price-target-raised-to-210-from-200-at-oppenheimer-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OPY","PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128000407","title":"Stock Track | Palvella Therapeutics Soars 6.18% Intraday on Narrowed Loss and Positive Clinical Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=1128000407","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128000407?lang=en_us&edition=fundamental","pubTime":"2026-03-31 21:35","pubTimestamp":1774964128,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics' stock surged 6.18% during Tuesday's intraday trading session following the release of its full year 2025 financial results and a comprehensive corporate update.The...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623586519","title":"Palvella Therapeutics 2025 Net Loss Narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2623586519","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623586519?lang=en_us&edition=fundamental","pubTime":"2026-03-31 19:49","pubTimestamp":1774957745,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics  reported a 2025 net loss Tuesday of $3.71 per diluted share, narrowing from a loss of $7.83 a year earlier.Analysts polled by FactSet expected a loss of $3.52.As expected, no revenue for the year ended Dec. 31 was reported.As of Dec. 31, the company said it had $58 million in cash and cash equivalents.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623585056","title":"BRIEF-Palvella Therapeutics Reports Full Year 2025 Financial Results And Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2623585056","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623585056?lang=en_us&edition=fundamental","pubTime":"2026-03-31 19:41","pubTimestamp":1774957291,"startTime":"0","endTime":"0","summary":"BRIEF-Palvella Therapeutics Reports Full Year 2025 Financial Results And Provides Corporate UpdateMarch 31 (Reuters) - Palvella Therapeutics Inc PVLA.O:PALVELLA THERAPEUTICS REPORTS FULL YEAR 2025 FIN","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nTUA7JL2VD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623585459","title":"Earnings Flash (PVLA) Palvella Posts 2025 Loss $3.71 a Share, vs. FactSet Est of $3.57 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2623585459","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623585459?lang=en_us&edition=fundamental","pubTime":"2026-03-31 19:33","pubTimestamp":1774956794,"startTime":"0","endTime":"0","summary":"Earnings Flash (PVLA) Palvella Posts 2025 Loss $3.71 a Share, vs. FactSet Est of $3.57 Loss","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623585151","title":"Palvella Therapeutics Q4 EPS $(1.08) Misses $(0.91) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2623585151","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623585151?lang=en_us&edition=fundamental","pubTime":"2026-03-31 19:31","pubTimestamp":1774956707,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics (NASDAQ:PVLA) reported quarterly losses of $(1.08) per share which missed the analyst consensus estimate of $(0.91) by 18.29 percent. This is a 79.89 percent increase over losses of $(5.37) per","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51563010/palvella-therapeutics-q4-eps-1-08-misses-0-91-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623958512","title":"Palvella Therapeutics Inc - Phase 3 Trial of Qtorin Rapamycin for Cutaneous Vms Planned for 2H 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2623958512","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623958512?lang=en_us&edition=fundamental","pubTime":"2026-03-31 19:30","pubTimestamp":1774956601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nTUA7JL2VD:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623585128","title":"Palvella Therapeutics - Nda for Qtorin Rapamycin for Treatment of Microcystic Lymphatic Malformations on Track for Planned Submission in H2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2623585128","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623585128?lang=en_us&edition=fundamental","pubTime":"2026-03-31 19:30","pubTimestamp":1774956601,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nTUA7JL2VD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623452585","title":"Palvella Therapeutics Inc - Phase 2 Trial of Qtorin Rapamycin for Angiokeratomas Planned for Q2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2623452585","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623452585?lang=en_us&edition=fundamental","pubTime":"2026-03-31 19:30","pubTimestamp":1774956601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nTUA7JL2VD:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PVLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623854835","title":"Press Release: Palvella Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2623854835","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623854835?lang=en_us&edition=fundamental","pubTime":"2026-03-31 19:30","pubTimestamp":1774956600,"startTime":"0","endTime":"0","summary":"New Drug Application  for QTORIN rapamycin for the treatment of microcystic lymphatic malformations  on track for planned submission in second half of 2026. Accelerating U.S. launch readiness for QTORIN rapamycin for microcystic LMs; potential to become the first FDA-approved therapy and first-line, standard-of-care treatment for serious, lifelong disease affecting an estimated more than 30,000 diagnosed patients in the U.S.Initiation of Phase 3 trial of QTORIN rapamycin for the treatment of cutaneous venous malformations planned for second half of 2026. Initiation of Phase 2 trial of QTORIN rapamycin for the treatment of clinically significant angiokeratomas planned for second quarter of 2026. Initiation of Phase 2 trial of QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis planned for second half of 2026. Pro forma cash of approximately $274 million as of December 31, 2025 reflects net proceeds from a February 2026 equity financing; cash and cash ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4555","LABU","03160","BK4022","TM","BK4588","BK4099","BK4232","PVLA","BK4585","BK4604","BK4139","R"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623314464","title":"Palvella says QTORIN rapamycin gel meets primary endpoint in Phase 3 SELVA trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2623314464","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623314464?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:33","pubTimestamp":1774870383,"startTime":"0","endTime":"0","summary":"Palvella highlighted Phase 3 SELVA trial results showing QTORIN 3.9% rapamycin anhydrous gel met primary endpoint with statistically significant outcomes across all pre-specified endpoints.Systemic rapamycin exposure stayed below 2 ng/mL at all measured timepoints, supporting tolerability profile.Scientific review in Journal of Vascular Anomalies backed targeted topical rapamycin approach for microcystic lymphatic malformations, where no FDA-approved therapies exist.Publication emphasized early treatment in children to reduce risk of complications over time.Document did not state that SELVA results were previously presented or scheduled for future presentation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Palvella Therapeutics Inc. p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL6jjzFm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623931291","title":"Palvella Therapeutics Announces Scientific Publication in Journal of Vascular Anomalies Highlighting the Infiltrative Growth and Therapeutic Challenges of Microcystic Lymphatic Malformations","url":"https://stock-news.laohu8.com/highlight/detail?id=2623931291","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623931291?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:30","pubTimestamp":1774870200,"startTime":"0","endTime":"0","summary":"Review delineates differences in clinical strategies between microcystic and macrocystic lymphatic malformations to guide disease-specific clinical trial design and treatment approaches Manuscript emp","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/30/3264521/0/en/Palvella-Therapeutics-Announces-Scientific-Publication-in-Journal-of-Vascular-Anomalies-Highlighting-the-Infiltrative-Growth-and-Therapeutic-Challenges-of-Microcystic-Lymphatic-Mal.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BK4139","PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623315199","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2623315199","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623315199?lang=en_us&edition=fundamental","pubTime":"2026-03-30 18:00","pubTimestamp":1774864800,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·INmune Bio Inc.                                 4Q      (.26)  4:05 PM. ·Dave & Buster                                   4Q       .39   4:05 PM. ·NIKE Class B                                     3Q       .29   4:15 PM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMNN","BTBT","MKC.V","BEEM","MSM","AEHR","BITF","FC","PVLA","BNZI","PHR","AIRO","JILL","APOG","KEEL","PRGS","PLAY","BCAX","NCNO","AIRJ","NNOX","BIRD","AYI","CALM","CAG","NEOG","NGEN","RNXT","PROP","CRDL","BYND","MAZE","AURA","PENG","FDS","BHST","PRPL","ANGO","SGML","MKC","SGMO","DMAC","INMB","INV","NKE","NMRA","RH","LNN","LW","NKLR","PVH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622783458","title":"Palvella Therapeutics announces Phase 2 DSAP trial start in H2 2026; Phase 3 SELVA study meets primary endpoint on mLM-IGA (p<0.001)","url":"https://stock-news.laohu8.com/highlight/detail?id=2622783458","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622783458?lang=en_us&edition=fundamental","pubTime":"2026-03-27 22:30","pubTimestamp":1774621836,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics announces Phase 2 DSAP trial start in H2 2026; Phase 3 SELVA study meets primary endpoint on mLM-IGA . Palvella reported that it will present two posters at the 2026 American Academy of Dermatology Annual Meeting, including data on QTORIN rapamycin topical formulation work and an interview study on porokeratosis burden.In the QTORIN rapamycin poster, the company described its Phase 3 SELVA study in microcystic lymphatic malformations as having met the primary endpoint on mLM-IGA  and reported rapamycin systemic levels below 2 ng/mL at all measured timepoints.The porokeratosis poster summarizes 10 qualitative interviews conducted with patients (n=9) and a caregiver (n=1) to assess physical, psychosocial, cancer-related, and treatment burdens.Palvella said it plans to start a Phase 2 trial of QTORIN pitavastatin for disseminated superficial actinic porokeratosis in the second half of 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nNDL37xXwV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","SG9999014013.SGD","LU2095319765.USD","BK4112","SG9999014005.SGD","BK4588","SG9999014021.USD","IE00BN0W2T93.GBP","LU2210150020.SGD","IE00BGHQF748.EUR","IE00BKPKM429.USD","IE00B64PRP62.GBP","IE00BN0W2W23.USD","BK4585","IE00BN0W2V16.EUR","LU0314104364.USD","PVLA","NDAQ","BK4139","IE00B3QW5Z07.USD","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":6,"totalSize":133,"code":"91000000","status":"200"}]}}